Mitochondria-Targeting Chemodynamic Therapy Nanodrugs for Cancer Treatment

Chen, Qiaohui; Li, Nian-Sheng; Wang, Xiaoyuan; Yang, Yuqi; Xiang, Yuting; Long, Xuejun; Zhang, Jinping; Huang, Jia; Chen, Li; Huang, Qiong

doi:10.3389/fphar.2022.847048

Cited by 17 publications

(19 citation statements)

References 60 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reactive oxygen species (ROS) are highly reactive and, at high concentrations, they can react with unsaturated lipids in lysosomal membranes to trigger LMP ( Huang et al, 2017 ). CDT kills cancer cells by converting the high concentrations of endogenous H 2 O 2 in cancer cells into the highly oxidative OH through the Fenton reaction ( Chen et al, 2022 ). CDT has very excellent selectivity and causes few side effects because tumors have much higher H 2 O 2 concentrations than normal tissue ( Tang et al, 2019 ).…”

Section: Cdt-induced Lysosomal Membrane Permeabilizationmentioning

confidence: 99%

Nanodrugs Detonate Lysosome Bombs

Xiang

Liu

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Cancer cell lysosomes contain various hydrolases and non-degraded substrates that are corrosive enough to destroy cancer cells. However, many traditional small molecule drugs targeting lysosomes have strong side effects because they cannot effectively differentiate between normal and cancer cells. Most lysosome-based research has focused on inducing mild lysosomal membrane permeabilization (LMP) to release anticancer drugs from lysosomal traps into the cancer cell cytoplasm. In fact, lysosomes are particularly powerful “bombs”. Achieving cancer cell-selective LMP induction may yield high-efficiency anticancer effects and extremely low side effects. Nanodrugs have diverse and combinable properties and can be specifically designed to selectively induce LMP in cancer cells by taking advantage of the differences between cancer cells and normal cells. Although nanodrugs-induced LMP has made great progress recently, related reviews remain rare. Herein, we first comprehensively summarize the advances in nanodrugs-induced LMP. Next, we describe the different nanodrugs-induced LMP strategies, namely nanoparticles aggregation-induced LMP, chemodynamic therapy (CDT)-induced LMP, and magnetic field-induced LMP. Finally, we analyze the prospect of nanodrugs-induced LMP and the challenges to overcome. We believe this review provides a unique perspective and inspiration for designing lysosome-targeting drugs.

show abstract

Section: Cdt-induced Lysosomal Membrane Permeabilizationmentioning

confidence: 99%

Nanodrugs Detonate Lysosome Bombs

Xiang

Liu

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Chen et al (2019) constructed a core-shell magnetic nanoparticle (FeNP) to load oxaliplatin (the third-generation star product of platinum-based drugs) with a modified tumor-targeting peptide (α-enolase-targeting peptide, ETP) (ETP-PtFeNP). The ETP-PtFeNP induced intracellular Fenton’s reaction and elicited ROS bursting ( Chen et al, 2022 ), which was partially beneficial for ICD. ERS-mediated ICD activation was demonstrated by markedly elevated levels of CRT on the cell surface in the ETP-PtFeNP–treated group.…”

Section: Nanodrug-based Strategies To Amplify Endoplasmic Reticulum S...mentioning

confidence: 99%

Nanodrugs Manipulating Endoplasmic Reticulum Stress for Highly Effective Antitumor Therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide due to high morbidity and mortality. Many attempts and efforts have been devoted to fighting cancer. Owing to the significant role of the endoplasmic reticulum (ER) in cell function, inducing ER stress can be promising for cancer treatment. However, the sustained activation of cytoprotective unfolded protein response (UPR) presents a tremendous obstacle for drugs in inducing unsolved ER stress in tumor cells, especially small-molecule drugs with poor bioavailability. Therefore, many emerging nanodrugs inducing and amplifying ER stress have been developed for efficient cancer treatment. More importantly, the novel discovery of ER stress in immunogenic cell death (ICD) makes it possible to repurpose antitumor drugs for immunotherapy through nanodrug-based strategies amplifying ER stress. Therefore, this mini-review aims to provide a comprehensive summary of the latest developments of the strategies underlying nanodrugs in the treatment of cancer via manipulating ER stress. Meanwhile, the prospects of ER stress–inducing nanodrugs for cancer treatment are systematically discussed, which provide a sound platform for novel therapeutic insights and inspiration for the design of nanodrugs in treating cancer.

show abstract

“…This is one of the unique advantages of CDT. So far, CDT nanodrugs with mitochondria-targeting displayed outstanding spatial specificity and anti-tumor effect ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Current Progress in Cancer Treatment Using Nanomaterials

et al. 2022

View full text Add to dashboard Cite

The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size have special optical, magnetic, and electrical characteristics. Nanomaterials have been fabricated for cancer treatments to overcome cytotoxicity and low specificity, and improve drug capacity and bioavailability. Despite the increasing number of related studies, few nanodrugs have been approved for clinical use. To improve translation of these materials, studies of targeted drug delivery using nanocarriers are needed. Cytotoxicity, enhanced permeability and retention effects, and the protective role of the protein corona remain to be addressed. This mini-review summarizes new nanomaterials manufactured in studies and in clinical use, analyses current barriers preventing their translation to clinical use, and describes the effective application of nanomaterials in cancer treatment.

show abstract

Mitochondria-Targeting Chemodynamic Therapy Nanodrugs for Cancer Treatment

Cited by 17 publications

References 60 publications

Nanodrugs Detonate Lysosome Bombs

Nanodrugs Detonate Lysosome Bombs

Nanodrugs Manipulating Endoplasmic Reticulum Stress for Highly Effective Antitumor Therapy

Current Progress in Cancer Treatment Using Nanomaterials

Contact Info

Product

Resources

About